Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholestasis | 7 | 2022 | 157 | 2.570 |
Why?
|
| Cholestasis, Intrahepatic | 3 | 2022 | 58 | 1.540 |
Why?
|
| Biliary Atresia | 8 | 2018 | 206 | 1.410 |
Why?
|
| Rotavirus Infections | 5 | 2013 | 359 | 1.040 |
Why?
|
| Bilirubin | 6 | 2021 | 128 | 0.660 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 4 | 2024 | 420 | 0.550 |
Why?
|
| Premature Birth | 1 | 2021 | 418 | 0.520 |
Why?
|
| Rotavirus Vaccines | 2 | 2013 | 73 | 0.470 |
Why?
|
| Alagille Syndrome | 3 | 2022 | 48 | 0.410 |
Why?
|
| Immunization, Passive | 1 | 2013 | 128 | 0.390 |
Why?
|
| Bile Ducts | 1 | 2012 | 54 | 0.360 |
Why?
|
| Osteopontin | 1 | 2011 | 52 | 0.350 |
Why?
|
| Rotavirus | 2 | 2012 | 505 | 0.350 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2022 | 197 | 0.340 |
Why?
|
| Liver Diseases | 4 | 2024 | 385 | 0.330 |
Why?
|
| Up-Regulation | 1 | 2011 | 879 | 0.290 |
Why?
|
| Liver | 6 | 2023 | 1798 | 0.290 |
Why?
|
| Radioactive Tracers | 1 | 2006 | 20 | 0.260 |
Why?
|
| Liver Cirrhosis | 5 | 2023 | 898 | 0.250 |
Why?
|
| Blood Specimen Collection | 1 | 2006 | 47 | 0.250 |
Why?
|
| Carbon Isotopes | 1 | 2006 | 233 | 0.250 |
Why?
|
| Infant | 16 | 2025 | 13048 | 0.250 |
Why?
|
| Developmental Disabilities | 2 | 2024 | 755 | 0.240 |
Why?
|
| Liver Transplantation | 2 | 2025 | 1103 | 0.240 |
Why?
|
| Child, Preschool | 11 | 2025 | 14734 | 0.230 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 338 | 0.210 |
Why?
|
| Cognition | 3 | 2018 | 810 | 0.210 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1500 | 0.210 |
Why?
|
| Male | 28 | 2025 | 64938 | 0.210 |
Why?
|
| Child | 13 | 2025 | 25763 | 0.200 |
Why?
|
| Sirolimus | 1 | 2025 | 240 | 0.200 |
Why?
|
| Humans | 34 | 2025 | 132064 | 0.200 |
Why?
|
| Loss of Function Mutation | 1 | 2024 | 159 | 0.200 |
Why?
|
| Nutrition Assessment | 1 | 2023 | 127 | 0.190 |
Why?
|
| Female | 27 | 2025 | 70664 | 0.190 |
Why?
|
| Blood Glucose | 1 | 2006 | 1121 | 0.190 |
Why?
|
| Homozygote | 1 | 2024 | 547 | 0.190 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2022 | 93 | 0.180 |
Why?
|
| Graft Rejection | 1 | 2025 | 559 | 0.180 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2024 | 985 | 0.180 |
Why?
|
| Immunosuppressive Agents | 1 | 2025 | 673 | 0.170 |
Why?
|
| Severity of Illness Index | 3 | 2024 | 3089 | 0.170 |
Why?
|
| Prospective Studies | 6 | 2024 | 6570 | 0.170 |
Why?
|
| Severe Combined Immunodeficiency | 2 | 2011 | 106 | 0.160 |
Why?
|
| Failure to Thrive | 2 | 2018 | 91 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 2 | 2013 | 1049 | 0.160 |
Why?
|
| Liver Neoplasms | 2 | 2024 | 1381 | 0.160 |
Why?
|
| Mutation, Missense | 1 | 2024 | 933 | 0.150 |
Why?
|
| Neuropsychological Tests | 3 | 2018 | 989 | 0.150 |
Why?
|
| Animals, Newborn | 2 | 2013 | 1033 | 0.150 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 2 | 2015 | 37 | 0.150 |
Why?
|
| Catheterization, Central Venous | 1 | 2020 | 140 | 0.150 |
Why?
|
| Rumination, Cognitive | 1 | 2018 | 2 | 0.140 |
Why?
|
| Catheterization, Peripheral | 1 | 2020 | 130 | 0.140 |
Why?
|
| Memory, Episodic | 1 | 2018 | 28 | 0.140 |
Why?
|
| Etodolac | 1 | 2017 | 1 | 0.140 |
Why?
|
| Sarcopenia | 1 | 2018 | 57 | 0.140 |
Why?
|
| Portoenterostomy, Hepatic | 2 | 2018 | 60 | 0.140 |
Why?
|
| Growth Disorders | 1 | 2018 | 191 | 0.140 |
Why?
|
| Hyperbilirubinemia | 1 | 2017 | 42 | 0.130 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 48 | 0.130 |
Why?
|
| Enterohepatic Circulation | 1 | 2017 | 11 | 0.130 |
Why?
|
| Gestational Age | 1 | 2021 | 1226 | 0.130 |
Why?
|
| Thinking | 1 | 2017 | 34 | 0.130 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2017 | 88 | 0.120 |
Why?
|
| Infant, Newborn | 6 | 2021 | 8542 | 0.120 |
Why?
|
| Bone Density | 1 | 2018 | 367 | 0.120 |
Why?
|
| Zonula Occludens-2 Protein | 1 | 2015 | 7 | 0.120 |
Why?
|
| Adolescent | 10 | 2025 | 20542 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2024 | 846 | 0.120 |
Why?
|
| Pregnancy | 2 | 2021 | 7554 | 0.110 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2015 | 83 | 0.110 |
Why?
|
| Avitaminosis | 1 | 2014 | 4 | 0.110 |
Why?
|
| Hypertension, Portal | 1 | 2015 | 78 | 0.110 |
Why?
|
| Neonatal Screening | 1 | 2016 | 192 | 0.110 |
Why?
|
| Depressive Disorder | 1 | 2018 | 476 | 0.110 |
Why?
|
| Prednisolone | 1 | 2014 | 73 | 0.110 |
Why?
|
| Methylprednisolone | 1 | 2014 | 98 | 0.100 |
Why?
|
| Double-Blind Method | 4 | 2022 | 1656 | 0.100 |
Why?
|
| Memory | 1 | 2017 | 356 | 0.100 |
Why?
|
| Hypertension | 1 | 2022 | 1397 | 0.100 |
Why?
|
| Health Status | 1 | 2015 | 407 | 0.100 |
Why?
|
| Biopsy | 3 | 2023 | 1284 | 0.100 |
Why?
|
| Bias | 1 | 2013 | 143 | 0.100 |
Why?
|
| Bile Acids and Salts | 1 | 2014 | 255 | 0.090 |
Why?
|
| Rodent Diseases | 1 | 2011 | 17 | 0.090 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 4684 | 0.090 |
Why?
|
| Depressive Disorder, Major | 1 | 2017 | 440 | 0.090 |
Why?
|
| Viremia | 1 | 2011 | 133 | 0.080 |
Why?
|
| Ornithine Carbamoyltransferase Deficiency Disease | 1 | 2009 | 35 | 0.080 |
Why?
|
| Treatment Outcome | 6 | 2024 | 13000 | 0.080 |
Why?
|
| Animals | 4 | 2024 | 34804 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2013 | 569 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2018 | 848 | 0.070 |
Why?
|
| Lipids | 2 | 2023 | 561 | 0.070 |
Why?
|
| ROC Curve | 2 | 2023 | 600 | 0.070 |
Why?
|
| Mutation | 1 | 2021 | 6226 | 0.070 |
Why?
|
| Adult | 7 | 2024 | 31571 | 0.070 |
Why?
|
| Body Weight | 2 | 2023 | 994 | 0.070 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2006 | 38 | 0.060 |
Why?
|
| Global Health | 1 | 2012 | 645 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 2025 | 17389 | 0.060 |
Why?
|
| Capillaries | 1 | 2006 | 71 | 0.060 |
Why?
|
| Mice | 2 | 2013 | 18478 | 0.060 |
Why?
|
| Quality of Life | 1 | 2015 | 2158 | 0.060 |
Why?
|
| Biomarkers | 3 | 2022 | 3403 | 0.060 |
Why?
|
| Brain | 1 | 2017 | 3181 | 0.060 |
Why?
|
| Depression | 1 | 2013 | 1339 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2009 | 607 | 0.050 |
Why?
|
| Thrombosis | 1 | 2009 | 524 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2022 | 5168 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2018 | 795 | 0.050 |
Why?
|
| Incidence | 1 | 2012 | 3375 | 0.050 |
Why?
|
| Young Adult | 4 | 2024 | 9952 | 0.050 |
Why?
|
| Sugars | 1 | 2023 | 17 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2011 | 1192 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2011 | 3865 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 1439 | 0.050 |
Why?
|
| Vesicular Transport Proteins | 1 | 2024 | 123 | 0.050 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2022 | 24 | 0.050 |
Why?
|
| Endoglin | 1 | 2022 | 32 | 0.050 |
Why?
|
| Telomere | 1 | 2024 | 222 | 0.050 |
Why?
|
| Losartan | 1 | 2022 | 35 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2022 | 211 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2018 | 1234 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 137 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2024 | 573 | 0.040 |
Why?
|
| Fibrosis | 1 | 2022 | 421 | 0.040 |
Why?
|
| Umbilical Veins | 1 | 2020 | 68 | 0.040 |
Why?
|
| Risk Factors | 2 | 2012 | 10938 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 3009 | 0.040 |
Why?
|
| Drosophila | 1 | 2024 | 823 | 0.040 |
Why?
|
| Alleles | 1 | 2024 | 1683 | 0.040 |
Why?
|
| Cephalometry | 1 | 2018 | 35 | 0.040 |
Why?
|
| Catheterization | 1 | 2020 | 241 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2018 | 203 | 0.040 |
Why?
|
| Drosophila Proteins | 1 | 2024 | 777 | 0.040 |
Why?
|
| Motor Skills | 1 | 2018 | 82 | 0.030 |
Why?
|
| Disease Progression | 1 | 2024 | 2227 | 0.030 |
Why?
|
| Cues | 1 | 2018 | 101 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 105 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2017 | 142 | 0.030 |
Why?
|
| Prevalence | 1 | 2024 | 2657 | 0.030 |
Why?
|
| Reference Values | 1 | 2018 | 703 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2018 | 312 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2018 | 147 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2022 | 1400 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2018 | 378 | 0.030 |
Why?
|
| Child Development | 1 | 2018 | 271 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 761 | 0.030 |
Why?
|
| Students | 1 | 2018 | 263 | 0.030 |
Why?
|
| Jaundice | 1 | 2015 | 27 | 0.030 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2014 | 8 | 0.030 |
Why?
|
| Algorithms | 1 | 2022 | 1718 | 0.030 |
Why?
|
| North America | 1 | 2015 | 265 | 0.030 |
Why?
|
| International Cooperation | 1 | 2015 | 167 | 0.030 |
Why?
|
| Vitamin K | 1 | 2014 | 38 | 0.030 |
Why?
|
| Vitamin E | 1 | 2014 | 63 | 0.030 |
Why?
|
| Vitamin A | 1 | 2014 | 56 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2017 | 402 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 372 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 234 | 0.030 |
Why?
|
| Vitamins | 1 | 2014 | 112 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 3993 | 0.030 |
Why?
|
| Phenotype | 1 | 2024 | 4527 | 0.030 |
Why?
|
| Social Behavior | 1 | 2015 | 223 | 0.030 |
Why?
|
| Learning | 1 | 2017 | 370 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 3352 | 0.020 |
Why?
|
| Vitamin D | 1 | 2014 | 183 | 0.020 |
Why?
|
| Middle Aged | 2 | 2024 | 28993 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 1248 | 0.020 |
Why?
|
| Reaction Time | 1 | 2013 | 167 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 547 | 0.020 |
Why?
|
| Drainage | 1 | 2014 | 262 | 0.020 |
Why?
|
| Cholesterol | 1 | 2015 | 558 | 0.020 |
Why?
|
| Emotions | 1 | 2015 | 367 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2014 | 696 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1957 | 0.020 |
Why?
|
| Comorbidity | 1 | 2017 | 1606 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2014 | 439 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 2139 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1839 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2014 | 1572 | 0.020 |
Why?
|
| Obesity | 1 | 2022 | 2398 | 0.020 |
Why?
|
| Diarrhea, Infantile | 1 | 2010 | 35 | 0.020 |
Why?
|
| Dehydration | 1 | 2010 | 41 | 0.020 |
Why?
|
| Virus Shedding | 1 | 2010 | 82 | 0.020 |
Why?
|
| Diarrhea | 1 | 2011 | 331 | 0.020 |
Why?
|
| Compartment Syndromes | 1 | 2009 | 32 | 0.020 |
Why?
|
| Enoxaparin | 1 | 2009 | 44 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5412 | 0.020 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2009 | 48 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 3731 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2010 | 615 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2010 | 492 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 6444 | 0.020 |
Why?
|
| Decision Making | 1 | 2013 | 700 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2010 | 249 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3412 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2010 | 565 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2009 | 171 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1285 | 0.020 |
Why?
|
| Feces | 1 | 2010 | 753 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3842 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 1800 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2011 | 1754 | 0.010 |
Why?
|
| United States | 1 | 2014 | 11660 | 0.010 |
Why?
|